Navigation Links
WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
Date:12/18/2007

- Rawson to Oversee Scientific Integrity of WellGen Programs and Advance

Collaborations with Food and Beverage Industry Leaders -

NORTH BRUNSWICK, N.J., Dec. 18 /PRNewswire/ -- WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Nancy E. Rawson, M.Sc., Ph.D., as Chief Scientific Officer. Dr. Rawson fills a newly created position that will report directly to the CEO.

Dr. Rawson, 51, joins WellGen at a critical stage in its development, as the Company has just brought its first functional food ingredient product to market and is conducting human studies for its second, while seeking to significantly expand the number of ingredients in its pipeline. In addition, the Company is completing the installation of a new, state-of-the-art molecular biology and natural products chemistry laboratory.

Dr. Rawson comes to WellGen with an extensive background in food, nutrition and basic biomedical research. Dr. Rawson most recently worked at the Monell Chemical Senses Center in Philadelphia, PA, as an Associate Member. The Monell Center is an independent scientific institute dedicated to basic research on the senses of taste, smell and chemosensory irritation. During her tenure there, Dr. Rawson built relationships with well-recognized leaders in the food and beverage industry as well as with researchers throughout the world.

Previously, Dr. Rawson was a Senior Nutrition Research Associate at the Campbell Soup Company. She also has held numerous advisory and university teaching positions.

Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, "We are fortunate to have Nancy Rawson, who is an outstanding scientist, join our company, and we look to her to ensure that our products' scientific foundations will meet the very highest standards. Her background in both research and industry will also enable her to be an effective leader in working with partner companies to bring new functional foods and beverages to market."

Richard Morgan, CEO of Amphion Innovations plc (LSE: AMP), a leading investor in WellGen, said, "Nancy Rawson has an excellent reputation in the food industry and an exceptional track record of scientific accomplishments. These will help WellGen continue to establish its leading position in the growing functional foods and beverages industry."

During her career, Dr. Rawson has received numerous honors and awards in bioscience and nutrition, and has often been quoted in the media as an authority in these fields. She is a frequent lecturer and conference panelist, and has authored and collaborated on a wide range of publications for both academic and non-technical audiences. She graduated with a Bachelor of Science degree from Fairfield University, Fairfield, CT, earned a Masters of Science in Nutrition from the University of Massachusetts, Amherst, and received a Ph.D. in Biology from the University of Pennsylvania.

About Amphion Innovations plc

Amphion Innovations plc (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors. Amphion uses a focused, hands-on company building approach based on decades of experience in both the US and UK. On the web: http://www.amphionplc.com

About WellGen

WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for food, therapeutics, and dietary supplement markets with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effect of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases. Please visit our website at http://www.wellgen.com for more information.


'/>"/>
SOURCE WellGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. KGI Names Kerry Howell Vice President for Advancement
2. Vical Names Andrew de Guttadauro Vice President, Corporate Development
3. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
4. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
5. CryoLife Names Philip Theodore as Vice President, General Counsel
6. Genstar Names Michael Hurt to Its Strategic Advisory Board
7. PPD Names Daniel Darazsdi as Chief Financial Officer
8. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
9. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
10. Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
11. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017  VWR Corporation (NASDAQ: VWR), the leading global independent ... customers, today reported its financial results for the fourth quarter ... 4Q16 record quarterly net sales of ... organic basis. 4Q16 EMEA-APAC segment ... while the Americas net sales increased 2.5%, or down 0.9% ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
(Date:2/23/2017)... upscale Capitol Hill neighborhood, with its swanky shops, parks and cafés, ... treatment salon to set up shop. But there,s Hair ... bistro on E Madison Ave, and CEO Maria Botham ... clinic, we pride ourselves on being a destination for parents ... stigma associated with lice. Everyone can get lice – it ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, ... Recognition Reception at Purdue Research Park of West Lafayette, Indiana. , ... of outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This ...
Breaking Biology Technology:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):